Literature DB >> 2523689

Pharmacokinetics of single- and multiple-dose teicoplanin in healthy volunteers.

P L Carver1, C H Nightingale, R Quintiliani, K Sweeney, R C Stevens, E Maderazo.   

Abstract

Teicoplanin, an investigational glycopeptide antibiotic related chemically and microbiologically to vancomycin, has in vitro and in vivo activity against gram-positive aerobic and anaerobic bacteria. We compared the single- and multiple-dose pharmacokinetics of intravenous teicoplanin in healthy volunteers. Serum and urine samples were collected for 35 days after single-dose (3 mg/kg) and 72 days after multiple-dose (3 mg/kg per day for 21 days) administration. A three-exponent equation with zero-order input was fitted to concentrations in serum. The mean half-lives (t1/2s) were significantly different (P = 0.0075) after single- and multiple-dose administration (130 +/- 14.9 and 176 +/- 29.8 h, respectively). The clinically relevant t1/2 obtained from multiple-dose data was approximately 61 h. Total and renal clearances determined at steady state were not statistically different, indicating that teicoplanin is eliminated almost entirely by renal mechanisms.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2523689      PMCID: PMC171425          DOI: 10.1128/AAC.33.1.82

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

Review 1.  Protein binding of antimicrobials: clinical pharmacokinetic and therapeutic implications.

Authors:  W A Craig; P G Welling
Journal:  Clin Pharmacokinet       Date:  1977 Jul-Aug       Impact factor: 6.447

2.  Pharmacokinetics of teicoplanin in man after intravenous administration.

Authors:  G L Traina; M Bonati
Journal:  J Pharmacokinet Biopharm       Date:  1984-04

3.  A-16686, a new antibiotic from Actinoplanes. II. Biological properties.

Authors:  R Pallanza; M Berti; R Scotti; E Randisi; V Arioli
Journal:  J Antibiot (Tokyo)       Date:  1984-04       Impact factor: 2.649

4.  In vitro activity and human pharmacokinetics of teicoplanin.

Authors:  L Verbist; B Tjandramaga; B Hendrickx; A Van Hecken; P Van Melle; R Verbesselt; J Verhaegen; P J De Schepper
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

5.  Teichomycins, new antibiotics from Actinoplanes teichomyceticus nov. sp. IV. Separation and characterization of the components of teichomycin (teicoplanin).

Authors:  A Borghi; C Coronelli; L Faniuolo; G Allievi; R Pallanza; G G Gallo
Journal:  J Antibiot (Tokyo)       Date:  1984-06       Impact factor: 2.649

6.  Teicoplanin, antibiotics from Actinoplanes teichomyceticus nov. sp. VI. Chemical degradation: physico-chemical and biological properties of acid hydrolysis products.

Authors:  A Malabarba; P Strazzolini; A Depaoli; M Landi; M Berti; B Cavalleri
Journal:  J Antibiot (Tokyo)       Date:  1984-09       Impact factor: 2.649

7.  Early termination of a prospective, randomized trial comparing teicoplanin and flucloxacillin for treating severe staphylococcal infections.

Authors:  P Calain; K H Krause; P Vaudaux; R Auckenthaler; D Lew; F Waldvogel; B Hirschel
Journal:  J Infect Dis       Date:  1987-02       Impact factor: 5.226

8.  Charge and lipophilicity govern the pharmacokinetics of glycopeptide antibiotics.

Authors:  D H Pitkin; B A Mico; R D Sitrin; L J Nisbet
Journal:  Antimicrob Agents Chemother       Date:  1986-03       Impact factor: 5.191

  8 in total
  13 in total

Review 1.  Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy.

Authors:  Federico Pea; Pierluigi Viale; Federica Pavan; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

2.  Clinical efficacy of teicoplanin.

Authors:  P Calain; F Waldvogel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-02       Impact factor: 3.267

3.  Population pharmacokinetic study of teicoplanin in severely neutropenic patients.

Authors:  O Lortholary; M Tod; N Rizzo; C Padoin; O Biard; P Casassus; L Guillevin; O Petitjean
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

Review 4.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

5.  Teicoplanin pharmacokinetics in patients undergoing continuous ambulatory peritoneal dialysis after intravenous and intraperitoneal dosing.

Authors:  D R Guay; W M Awni; C E Halstenson; M T Kenny; W F Keane; G R Matzke
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

Review 6.  Clinical pharmacokinetics of teicoplanin.

Authors:  M Rowland
Journal:  Clin Pharmacokinet       Date:  1990-03       Impact factor: 6.447

Review 7.  Teicoplanin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.

Authors:  D M Campoli-Richards; R N Brogden; D Faulds
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

Review 8.  Teicoplanin: 10 years of clinical experience.

Authors:  M Trautmann; H Wiedeck; M Ruhnke; M Oethinger; R Marre
Journal:  Infection       Date:  1994 Nov-Dec       Impact factor: 3.553

9.  Implementation and evaluation of a stochastic control strategy for individualizing teicoplanin dosage regimen.

Authors:  M Tod; P Alet; O Lortholary; O Petitjean
Journal:  J Pharmacokinet Biopharm       Date:  1997-12

10.  Experience with outpatient intravenous teicoplanin therapy for chronic osteomyelitis.

Authors:  W Graninger; C Wenisch; E Wiesinger; M Menschik; J Karimi; E Presterl
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-07       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.